AlphaMadera's AlphaVal page computes Ultragenyx Pharmaceutical Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag RARE as undervalued, fairly valued, or overvalued.

What is Ultragenyx Pharmaceutical Inc.'s fair value?

Fair value for RARE is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value RARE?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from RARE's most recent reported fundamentals.

RARE - Ultragenyx Pharmaceutical Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $46.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: RARE has had negative net income and negative EPS in all 5 available fiscal year(s). Quality gate: persistently unprofitable companies are excluded.